Pacira BioSciences has reached a settlement with Fresenius Kabi and other companies regarding patent litigation for its non-opioid pain therapy EXPAREL, allowing limited generic entry beginning in early 2030.
Pacira BioSciences has dosed the first patient in its Phase 2 ASCEND study evaluating PCRX-201, a locally administered gene therapy designed to treat osteoarthritis of the knee by boosting anti-inflammatory protein production.
Pacira BioSciences has received FDA clearance for its Iovera system with a longer-needle Smart Tip to treat chronic low back pain, offering a drug-free alternative.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.